Cannabinoid receptor with an 'identity crisis' gets a second look

@article{Rogers2015CannabinoidRW,
  title={Cannabinoid receptor with an 'identity crisis' gets a second look},
  author={Nala Rogers},
  journal={Nature Medicine},
  year={2015},
  volume={21},
  pages={966-967}
}
  • Nala Rogers
  • Published 4 September 2015
  • Psychology, Medicine
  • Nature Medicine
Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?
TLDR
Interestingly, endocannabinoid system modulation might be one of the mechanisms at the basis of the reported efficacy of exercise and physical therapy in CIPN patients, and possible virtuous interplay will be discussed in this review. Expand
Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases
TLDR
An updated review of pre-clinical and clinical studies, the adequacy/inadequacy of cannabinoid-based therapeutics in various pathological conditions is highlighted, and alternative strategies to modulate endocannabinoid tone, and future directions are emphasized. Expand
Cannabinoid type 2 receptor agonist JWH133 decreases blood pressure of spontaneously hypertensive rats through relieving inflammation in the rostral ventrolateral medulla of the brain.
TLDR
It is suggested that exciting the CB2 receptor relieves proinflammatory cytokine levels in the RVLM to decrease the BP, HR and RSNA in SHRs. Expand
Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats.
TLDR
Evidence is provided that paclitaxel induced microglia dysregulation and epigenetically upregulated the microglial expression of BDNF, which led to sensitization of dorsal horn neurons and mechanical allodynia in rats, and MDA7 alleviated these pathological processes. Expand
The Impact of Cannabinoid Receptor 2 Deficiency on Neutrophil Recruitment and Inflammation.
TLDR
Recent work in preclinical models of inflammation raises two questions: by what mechanisms do CB2 agonists provide anti-inflammatory effects during acute inflammation and what challenges exist in the translation of CB2 modulating therapeutics into the clinic. Expand
An overview of the cannabinoid type 2 receptor system and its therapeutic potential
TLDR
A narrative review summarizes recent insights into the role of the cannabinoid type 2 (CB2) receptor as potential therapeutic target in neuropathic pain and neurodegenerative conditions. Expand
General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation
TLDR
A thorough understanding of major pain conditions that the authors experience—nociceptive, inflammatory and physiologically dysfunction, such as neuropathic pain and its modulation and feedback systems is put in place. Expand
Novel multi‐target directed ligand‐based strategies for reducing neuroinflammation in Alzheimer's disease
TLDR
CatB, DUSP2 and MAGL inhibitors show promising preclinical anti‐inflammatory effects in vivo and in vitro, and incorporating pharmacophores that inhibit these targets into MTDLs represents a promising avenue towards effective suppression of neuroinflammation associated with AD. Expand
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
TLDR
The most extensive characterization of the molecular pharmacology of the most widely used CB2R ligands to date is reported, identifying marked differences in the ability of certain agonists to activate distinct signalling pathways and to cause off-target effects. Expand
...
1
2
...

References

SHOWING 1-10 OF 14 REFERENCES
Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor.
TLDR
2,5,6-substituted pyridines as a novel class of potential CB2 PET ligands investigated for their potency and binding properties toward human and rodent CB1 and CB2 and 16 is a promising radiotracer for imaging CB2 in rodents. Expand
CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
TLDR
This review summarizes the present knowledge of CB2 receptor signaling, localization, and regulation, and discusses the availability of genetic tools to study CB2 receptors and also provides an update on preclinical data on CB2 agonists in pain models. Expand
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice
TLDR
It is found that CB2R genes and receptors are expressed in midbrain DA neurons, and that activation of CB2Rs inhibits DA neuronal firing and i.v. cocaine self-administration, suggesting that brain CB 2Rs may constitute a new therapeutic target in medication development for treatment of a number of CNS disorders. Expand
Validating Antibodies to the Cannabinoid CB2 Receptor
TLDR
This work is the first to develop a label-free method of protein detection using mass spectrometry that, with further refinement, could provide unequivocal identification of CB2 receptor protein in native tissues. Expand
Antibody testing for brain immunohistochemistry: Brain immunolabeling for the cannabinoid CB2 receptor
TLDR
The results showed that great caution needs to be exercised when interpreting the results of brain immunohistochemistry using CB₂ receptor antibodies and that, in general, none of the tests for antibody validity that have been proposed, apart from the knockout control test, are reliable. Expand
Effects on Immune Cells of a New 1,8-Naphthyridin-2-One Derivative and Its Analogues as Selective CB2 Agonists: Implications in Multiple Sclerosis
TLDR
Assessment of the potential immune-modulatory effects of novel compounds in activated lymphocytes isolated from MS patients with respect to healthy controls suggests potential application of these drugs in neuro-inflammation, supporting further investigations of the effects of compounds in the therapy of MS. Expand
A new cannabinoid CB2 receptor agonist HU‐910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury
TLDR
Cannabinoid CB2 receptor activation has been reported to attenuate myocardial, cerebral and hepatic ischaemia‐reperfusion (I/R) injury and this data confirms that activation of this receptor results in attenuated I/R injury. Expand
Cannabinoid receptors: nomenclature and pharmacological principles
The CB1 and CB2 cannabinoid receptors are members of the G protein-coupled receptor (GPCR) family that are pharmacologically well defined. However, the discovery of additional sites of action forExpand
A Randomized, Controlled Study to Investigate the Analgesic Efficacy of Single Doses of the Cannabinoid Receptor-2 Agonist GW842166, Ibuprofen or Placebo in Patients With Acute Pain Following Third Molar Tooth Extraction
TLDR
Ibuprofen was significantly more effective than placebo across all endpoints and there was no evidence for any beneficial adjunctive effect after coadministration of rescue analgesia with GW842166. Expand
Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy
TLDR
The CB2 receptor is expressed by podocytes, and in experimental diabetes, CB2 activation ameliorates both albuminuria and podocyte protein loss, suggesting a protective effect of signaling through CB2 in DN. Expand
...
1
2
...